| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
9.16(B) |
| Last
Volume: |
875,140 |
Avg
Vol: |
504,506 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
40,296 |
45,669 |
50,307 |
151,828 |
| Total Sell Value |
$7,357,263 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
| Total People Sold |
2 |
4 |
5 |
6 |
| Total Sell Transactions |
3 |
5 |
7 |
17 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gebski Christine |
See Remarks |
• – – |
2023-03-03 |
4 |
D |
$188.00 |
$23,688 |
D/D |
(126) |
32,909 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
375 |
33,035 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,468 |
21,922 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
8,348 |
17,487 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
19,393 |
184,967 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,848 |
32,970 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,467 |
32,660 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2023-03-02 |
4 |
D |
$176.37 |
$1,176,388 |
D/D |
(6,670) |
165,574 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-03-02 |
4 |
D |
$174.37 |
$109,853 |
D/D |
(630) |
29,193 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2023-02-28 |
4 |
D |
$173.28 |
$476,173 |
D/D |
(2,748) |
172,244 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-02-28 |
4 |
D |
$173.28 |
$79,709 |
D/D |
(460) |
29,823 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2023-02-28 |
4 |
D |
$173.28 |
$90,279 |
D/D |
(521) |
28,122 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2023-02-28 |
4 |
D |
$173.28 |
$62,034 |
D/D |
(358) |
18,454 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2023-02-28 |
4 |
D |
$173.44 |
$118,286 |
D/D |
(682) |
28,643 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2023-02-28 |
4 |
D |
$173.44 |
$79,436 |
D/D |
(458) |
18,812 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2023-02-28 |
4 |
D |
$173.44 |
$103,023 |
D/D |
(594) |
9,139 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-02-28 |
4 |
D |
$173.44 |
$78,395 |
D/D |
(452) |
30,283 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2023-02-28 |
4 |
D |
$173.44 |
$567,669 |
D/D |
(3,273) |
174,992 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2023-02-16 |
4 |
AS |
$200.00 |
$1,129,400 |
D/D |
(5,647) |
29,325 |
|
-30% |
|
| Madaus Martin D |
Director |
– • – |
2023-02-06 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
2 |
|
- |
|
| Madaus Martin D |
Director |
– • – |
2023-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
111 |
111 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2022-11-11 |
4 |
AS |
$200.00 |
$5,000,000 |
D/D |
(25,000) |
178,265 |
|
-16% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2022-11-11 |
4 |
OE |
$33.87 |
$846,750 |
D/D |
25,000 |
203,265 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2022-10-07 |
4 |
OE |
$59.52 |
$27,736 |
D/D |
466 |
34,972 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2022-09-09 |
4 |
S |
$227.17 |
$176,057 |
D/D |
(775) |
76,401 |
|
18% |
|
647 Records found
|
|
Page 4 of 26 |
|
|
0.91 (0.61%) 
